What Does a DXA Scan Measure?
A dual-energy X-ray absorptiometry scan, usually called a DXA or DEXA scan, estimates how much mineral is present in bone. It does not directly measure bone strength, diagnose every possible cause of fracture, or provide a stand-alone probability of breaking a bone. Instead, it measures bone mineral density, or BMD, at specific anatomical sites—most often the lumbar spine and hip—and reports these measurements both in grams per square centimeter and as age-matched T-scores or younger-adult Z-scores. These measurements help clinicians identify low bone mass and estimate fracture risk, but the result must be interpreted alongside age, history of fragility fractures, steroid exposure, other illnesses, mobility, falls, smoking, alcohol use, and family history. A technically accurate scan can still be clinically unhelpful if it is performed unnecessarily or interpreted without this context. The scan itself is noninvasive, uses low radiation, and generally takes about 10 to 20 minutes, although preparation and positioning can make the total visit longer.
Also worth reading: Should You Test SHBG and Total Testosterone Together, and How Are the Results Interpreted? · How Are DXA Bone Density Results Interpreted Without the Confusing T-Score Terms? · How Can Someone Defend a Probation Drug Test After a Positive Result?
A DXA result is therefore best understood as one part of a fracture-risk assessment rather than a universal pass-or-fail test. This distinction matters because a person with a relatively acceptable T-score can still fracture if they have recently fallen multiple times, use long-term corticosteroids, or already have a hip or vertebral fracture. Conversely, some people have a moderately reduced T-score but a low overall short-term risk. The same general measurement principles apply to peripheral quantitative CT and other imaging methods, but they are not interchangeable with DXA, and results from one technique should not be converted informally into another. DXA remains one of the standard ways to diagnose osteoporosis at the population level, monitor selected treatment decisions, and screen people who may need preventive care.
How Are T-Scores and Z-Scores Interpreted?
For postmenopausal women and men aged 50 or older, the World Health Organization standard is commonly expressed through the hip or lumbar-spine T-score, which compares the measured BMD with the average BMD of a healthy young adult. A T-score at or below -2.5 is classified as osteoporosis, while a T-score from -1.0 to -2.4 at a site is generally classified as low bone mass, often called osteopenia. These are diagnostic categories rather than perfect divisions between people who will and will not fracture. The National Osteoporosis Foundation, commonly referred to as the Bone Health and Osteoporosis Foundation in the United States, uses a somewhat broader treatment approach that considers hip or spine osteoporosis, as well as certain higher-risk clinical factors, rather than relying only on whether a T-score crosses -2.5. A person can qualify for treatment even with a T-score above -2.5 when their combined risk is sufficiently high.
Younger adults are assessed primarily with Z-scores, which compare bone density with people of the same age. For example, a Z-score below -2.0 is described as “below the expected range for age,” but it should not automatically be labeled osteoporosis solely because of that number. In children, interpreting growth, puberty, developmental delay, and skeletal size becomes especially important. Men under 50, women under 50, and anyone evaluated for a secondary cause of low bone mass also require a different clinical framework. When the lowest T-score at the lumbar spine or total hip determines a diagnosis, clinical practice may reference the lowest site, but inconsistency between sites is common and does not always require several separate diagnoses.
| DXA feature | Hip or lumbar-spine result | Clinical meaning in a typical adult aged 50 or older |
|---|---|---|
| Normal | T-score -1.0 or higher | Does not eliminate risk from falls, fragility fractures, medications, or systemic disease |
| Low bone mass | T-score -1.1 to -2.4 | Often called osteopenia; treatment depends on calculated fracture risk and other factors |
| Osteoporosis | T-score -2.5 or lower at hip or lumbar spine | Requires assessment of causes, fall risk, and treatment options |
| Very low BMD | T-score -3.0 or lower | Indicates especially low density, but the same site, technology, and patient factors must be confirmed |
| Below expected range for age | Z-score -2.0 or lower | More useful conceptually in younger adults than a standard T-score diagnosis |
Why Can Two DXA Reports Look Different?
A surprisingly large amount of variation can arise from the machine, software, positioning, calibration, body shape, or choice of measurement site. DXA measures attenuation through bone and soft tissue using two X-ray energies, and the machine estimates bone mineral from those signals. Tight clothing, jewelry, metal implants, recent contrast, severe obesity, very small body size, scoliosis, prior surgery, or movement during the scan may influence the image. Femoral-neck positioning is particularly sensitive: slight rotation and changes in which part of the neck is selected can shift the result. If a report says that the scan is technically poor or has artifacts, repeating it under better conditions may be more useful than debating whether a borderline number should be treated as a diagnosis.
Clinically significant change between scans must also be interpreted carefully. The least significant change, or LSC, is the amount of difference beyond which the change is likely to be real rather than measurement noise. This threshold is calculated for a specific scanner and precision assessment, so two laboratories may use different values. A 3% to 5% rise at the total hip sometimes appears in patient summaries, but it is not a universal personal threshold and should not replace the facility’s LSC. The lumbar spine has more measurement variability than the total hip in many people. If BMD rises after treatment, the meaningful question is whether the change exceeds measurement error; medication response is judged mainly by reducing fracture, preventing further loss, and lowering relevant risk markers rather than requiring every BMD value to rise.
Follow-up DXA is not needed for everyone on the same schedule. The Bone Health and Osteoporosis Foundation often suggests repeating DXA after one to two years when treatment decisions may depend on a meaningful BMD response, and less frequently—often several years—when the result is not likely to change management. Tests should not be repeated simply because a portal schedules them automatically. Compare the same anatomical site on the same or a calibrated machine, review whether the new report matches the prior one, and avoid “shopping” for a better result by switching techniques or facilities without an appropriate reason.
What Risk Information Should Accompair the Scan?
A formal fracture-risk estimate can improve interpretation, especially when the DXA is normal, borderline, or affected by a condition that produces very high risk. In the United States, the Fracture Risk Assessment Tool, or FRAX, estimates the probability of major osteoporotic fracture over 10 years and hip fracture over five years. It uses age, sex, weight, height, prior fractures, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, alcohol use, and femoral-neck BMD. FRAX does not include falls, most doses of some osteoporosis medications, lumbar-spine BMD, or every relevant disorder, so a clinician must adjust or supplement the result rather than treat it as a complete calculation. It is also less reliable below age 40, above age 90, in people with very high BMD, and in populations substantially different from those in the original datasets.
For postmenopausal women and men aged 50 or older, a commonly used U.S. threshold is a 10-year major osteoporotic fracture risk of 20% or higher, or a hip-fracture probability of 3% or higher, although the Bone Health and Osteoporosis Foundation’s treatment recommendations use another framing for very high risk. Labels such as “high risk” should therefore be tied to the named calculator and guidance being used. A clinician may also classify someone as very high risk after a recent hip or spine fracture, multiple fractures, or sustained glucocorticoid exposure. These situations can justify action even when the scan is not the sole reason.
A written interpretation is more useful than a number alone. Ask whether the report identifies the lowest qualifying T-score, whether the scan quality is acceptable, whether the same site can be compared over time, and what the clinician expects to do with the result. A good consultation also covers calcium and vitamin D intake, resistance and balance exercise, fall prevention, medications, alcohol, smoking, and safe use of stairs and walking surfaces. DXA does not measure fall frequency or determine whether a vertebral fracture is already present; those questions require separate assessment and, when indicated, spine imaging.
DXA Compared With Other Bone Tests
DXA is widely available, relatively inexpensive, reproducible at the lumbar spine and hip, and validated for predicting fracture risk. It is therefore the default central densitometry technique for many adults, but not for every question. Standard X-rays do not measure BMD precisely enough to diagnose early osteoporosis, although they may show moderate or advanced bone loss and a radiologist may incidentally notice a vertebral fracture. A nuclear bone scan serves a different purpose: radiotracer uptake reflects bone remodeling and helps locate infection, metastasis, stress injury, or sometimes Paget disease rather than directly diagnosing low BMD. A DMSA scan is a kidney imaging test and has no role in osteoporosis diagnosis. CT can reveal fractures and other anatomy, and newer methods can estimate strength from CT data, but routine CT may involve more radiation and its BMD output depends on calibration and technique.
| Feature | DXA bone densitometry | Standard hip or spine X-ray | Nuclear medicine bone scan |
|---|---|---|---|
| Main purpose | Measure BMD and help assess fracture risk | Show fractures, alignment, arthritis, or some bone abnormalities | Show areas of altered bone turnover or tracer uptake |
| Typical radiation | Low, generally around 0.001 to 0.01 mSv for central DXA depending on protocol | Usually higher than DXA, with exact dose varying by examination | Uses a radiotracer and gamma camera; radiation depends on the agent and dose |
| Diagnoses early low bone mass | Yes, with appropriate interpretation | No, not reliably | No |
| Detects vertebral compression fracture | Sometimes incidentally, but not its primary role | Often, especially on a lateral spine image | It can detect increased uptake but is usually not the preferred first test for an occult vertebral fracture |
| Best use | Baseline and monitored assessment of osteoporosis | Fracture evaluation or opportunistic screening | Complex bone pain, infection, metastasis, or selected metabolic bone disease |
Common Mistakes in DXA Interpretation
n One common mistake is treating osteopenia as a mandatory prescription label. Osteopenia describes a measurement range, while medication is generally reserved for a confirmed osteoporosis diagnosis or a sufficiently high calculated or clinical fracture risk. A second mistake is assuming that a normal T-score makes no further action necessary. Older adults, people on long-term steroids, and those with recent weight loss, recurrent falls, or prior fragility fractures may remain vulnerable even when the T-score is above -2.5. Third, patients often compare the lumbar spine with the hip and wonder why the percentage changes; those sites can contain different proportions of cortical and trabecular bone, so they may genuinely behave differently.
Another error is diagnosing from a single number without confirming which age group and machine were used. A 70-year-old’s Z-score may look reassuring even when the T-score is very low, and a forearm or heel result should not be substituted for a central DXA threshold without considering the clinical context. People also frequently attribute a fracture to osteoporosis without evaluating causes such as vitamin D deficiency, hyperparathyroidism, malabsorption, multiple myeloma, thyroid disease, alcohol excess, or long-term corticosteroid exposure. Not every fracture occurs in low-BMD bone, and not every person with low BMD has osteoporosis.
Finally, a report can be technically poor, and “95% confidence” does not mean the person has a 95% lifetime chance of fracture. Precision describes measurement reliability, not personal prognosis. Machine quality flags, comparable prior reports, and longitudinal change should all be reviewed. Reliable interpretation requires a clinician who can combine the report with history and examination rather than a patient portal that merely highlights the lowest percentage.
When to Arrange Testing and When to Act?
Central DXA is often recommended for women aged 65 and older and postmenopausal women younger than 65 when risk is elevated. Men aged 70 and older are commonly offered testing, with earlier age-based testing when risk factors justify it. Younger adults may need DXA because of fragility fractures, prolonged glucocorticoid therapy, low body weight, other risk conditions, or suspected secondary osteoporosis, but age-specific pediatric and young-adult interpretation differs. Screening without a plan for follow-up is rarely helpful; the person should have access to a clinician who can explain risk and arrange treatment or preventive services when needed.
A recent low-trauma fracture should not be left unassessed while waiting for a DXA appointment. Prompt clinical evaluation can address pain stabilization, the cause of the fracture, fall risk, vitamin D or calcium problems, and whether osteoporosis treatment should begin immediately. A sudden severe back pain after a minor injury, loss of height, or new kyphosis deserves medical review because vertebral fractures can be overlooked. Chest or abdominal pain, shortness of breath, fever, severe new weakness, or suspected infection after surgery is not simply a “bone density” issue and needs timely assessment. New back pain with fever, neurologic symptoms, major trauma, or a history of cancer requires especially cautious evaluation.
Treatment decisions may follow established clinical pathways once someone meets diagnostic or risk criteria. Established options include bisphosphonates, denosumab, anabolic agents, and select hormonal or selective estrogen-receptor modulators. These are not interchangeable: some require administration by infusion or injection, some can create rebound bone loss if stopped improperly, and kidney function, dental status, fracture pattern, cancer history, laboratory results, pregnancy potential, and other risks affect selection. Calcium and vitamin D support the plan but are not substitutes for fracture-risk treatment when that treatment is indicated. Movement, protein intake, fall prevention, and review of medicines that increase falls or bone loss complete the clinical response.
What Does DXA Cost and Coverage Look Like?
In the United States, DXA is often inexpensive when ordered for a medically appropriate indication. Covered facility outpatient prices may range from about $100 to $400, while hospital outpatient or outpatient hospital billing can approach $700 to $1,500 or more. Prices vary by geography, facility type, insurance, and whether imaging centers charge a facility fee in addition to the professional fee. Many health plans cover screening at recommended ages, but prior authorization, age limits, and medical-necessity rules vary substantially. Medicare generally covers DXA for qualifying beneficiaries under defined diagnostic indications, but coverage does not mean every bill is fully paid. Cash prices negotiated at independent imaging centers may be lower than a hospital’s self-pay rate, yet patients should confirm whether the negotiated price includes both the scan and interpretation.
In other countries, access and payment are organized differently. National health services may fund DXA according to age and risk guidelines, while private insurance may require referral or prior authorization. Public-health initiatives, such as Ireland’s DXA Health Informatics Prediction project, show how registry data can help estimate the burden of low bone mass and osteoporosis, but prevalence figures from one population should not be applied automatically to another. Before scheduling, ask whether there will be a facility fee, whether the facility is in network, whether the clinician will interpret the result, and whether a repeat scan can be performed at the same facility. Lower cost is not automatically better if quality control is poor or the report lacks fracture-risk context. The most useful service is one that produces a valid measurement and a clinical plan, not merely a low-priced image.